DHTRF
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
DHTRF (DHTRF) - Net Assets
Latest net assets as of September 2025: $437.10 Million USD
Based on the latest financial reports, DHTRF (DHTRF) has net assets worth $437.10 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($909.05 Million) and total liabilities ($471.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $437.10 Million |
| % of Total Assets | 48.08% |
| Annual Growth Rate | 11.65% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.54 |
DHTRF - Net Assets Trend (2021–2024)
This chart illustrates how DHTRF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DHTRF (2021–2024)
The table below shows the annual net assets of DHTRF from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $527.53 Million | -5.75% |
| 2023-09-30 | $559.70 Million | +50.32% |
| 2022-09-30 | $372.34 Million | -1.75% |
| 2021-09-30 | $378.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to DHTRF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 648.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $554.67 Million | 105.15% |
| Total Equity | $527.53 Million | 100.00% |
DHTRF Competitors by Market Cap
The table below lists competitors of DHTRF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Mountain Finance Corporation
NASDAQ:NMFC
|
$76.97K |
|
DAIWA SEC GRP - Dusseldorf Stock Exchang
DU:DSE
|
$77.08K |
|
Trustpilot Group PLC
LSE:TRST
|
$77.09K |
|
MALAGASY MINER
BE:MGM
|
$77.19K |
|
Decoy Therapeutics Inc.
NASDAQ:DCOY
|
$76.95K |
|
HELIX ENERGY SOLNS
MU:CTV
|
$76.95K |
|
ASURE SOFTWARE (VTE1.SG)
STU:VTE1
|
$76.78K |
|
TAKIX
NMFQS:TAKIX
|
$76.73K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DHTRF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 559,699,000 to 527,531,000, a change of -32,168,000 (-5.7%).
- Net loss of 3,364,000 reduced equity.
- Dividend payments of 33,598,000 reduced retained earnings.
- Share repurchases of 3,917,000 reduced equity.
- New share issuances of 20,441,000 increased equity.
- Other factors decreased equity by 11,730,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.36 Million | -0.64% |
| Dividends Paid | $33.60 Million | -6.37% |
| Share Repurchases | $3.92 Million | -0.74% |
| Share Issuances | $20.44 Million | +3.87% |
| Other Changes | $-11.73 Million | -2.22% |
| Total Change | $- | -5.75% |
Book Value vs Market Value Analysis
This analysis compares DHTRF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.87x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | $9.70 | $8.12 | x |
| 2022-09-30 | $9.85 | $8.12 | x |
| 2023-09-30 | $9.93 | $8.12 | x |
| 2024-09-30 | $9.37 | $8.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DHTRF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.41%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.87x
- Recent ROE (-0.64%) is below the historical average (6.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 5.69% | 29.40% | 0.17x | 1.15x | $-16.34 Million |
| 2022 | 3.11% | 14.52% | 0.13x | 1.70x | $-25.64 Million |
| 2023 | 16.35% | 97.59% | 0.11x | 1.49x | $35.53 Million |
| 2024 | -0.64% | -2.41% | 0.14x | 1.87x | $-56.12 Million |
Industry Comparison
This section compares DHTRF's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DHTRF (DHTRF) | $437.10 Million | 5.69% | 1.08x | $76.97K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |